Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Gilead Sciences's enterprise value was $233.62B on Nov 11, 2026, against $173.80B a year earlier. Over the last 5 years it ranged from $94.58B to $234.80B, with a median of $124.80B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $233.62B | +37.5% |
| 2025 | Dec 31, 2025 | $169.95B | +27.6% |
| 2024 | Dec 31, 2024 | $133.22B | +11.9% |
| 2023 | Dec 29, 2023 | $119.07B | -6.4% |
| 2022 | Dec 30, 2022 | $127.19B | +12.5% |
| 2021 | Dec 31, 2021 | $113.07B | +44.3% |
| 2020 | Dec 31, 2020 | $78.34B | -6.9% |
| 2019 | Dec 31, 2019 | $84.13B | +5.2% |
| 2018 | Dec 31, 2018 | $79.94B | -15.8% |
| 2017 | Dec 29, 2017 | $94.92B | -13.7% |
| 2016 | Dec 30, 2016 | $109.97B | -28.4% |
| 2015 | Dec 31, 2015 | $153.67B | +5.2% |
| 2014 | Dec 31, 2014 | $146.06B | +21.0% |
| 2013 | Dec 31, 2013 | $120.74B | +92.0% |
| 2012 | Dec 31, 2012 | $62.89B | +118.3% |
| 2011 | Dec 30, 2011 | $28.81B | +2.7% |
| 2010 | Dec 31, 2010 | $28.05B | -26.1% |
| 2009 | Dec 31, 2009 | $37.98B | – |
See a number that looks wrong?